» Articles » PMID: 28117818

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy Against S. Pneumoniae, H. Influenzae, K. Pneumoniae, P. Aeruginosa or A. Baumannii

Overview
Journal J Vis Exp
Date 2017 Jan 25
PMID 28117818
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Efficacy of candidate antibacterial treatments must be demonstrated in animal models of infection as part of the discovery and development process, preferably in models which mimic the intended clinical indication. A method for inducing robust lung infections in immunocompetent rats and mice is described which allows for the assessment of treatments in a model of serious pneumonia caused by S. pneumoniae, H. influenzae, P. aeruginosa, K. pneumoniae or A. baumannii. Animals are anesthetized, and an agar-based inoculum is deposited deep into the lung via nonsurgical intratracheal intubation. The resulting infection is consistent, reproducible, and stable for at least 48 h and up to 96 h for most isolates. Studies with marketed antibacterials have demonstrated good correlation between in vivo efficacy and in vitro susceptibility, and concordance between pharmacokinetic/pharmacodynamic targets determined in this model and clinically accepted targets has been observed. Although there is an initial time investment when learning the technique, it can be performed quickly and efficiently once proficiency is achieved. Benefits of the model include elimination of the neutropenic requirement, increased robustness and reproducibility, ability to study more pathogens and isolates, improved flexibility in study design and establishment of a challenging infection in an immunocompetent host.

Citing Articles

The standardization and efficacy of fermented (L.) in combination with enrofloxacin against artificially induced pneumonic pasteurellosis in rat models.

Prakoso Y, Susilo A, Widyarini S Open Vet J. 2025; 14(12):3404-3416.

PMID: 39927353 PMC: 11799618. DOI: 10.5455/OVJ.2024.v14.i12.25.


The Coexistence of and Enhanced Biofilm Thickness but Induced Less Severe Neutrophil Responses and Less Inflammation in Pneumonia Mice Than Alone.

Phuengmaung P, Chongrak C, Saisorn W, Makjaroen J, Singkham-In U, Leelahavanichkul A Int J Mol Sci. 2024; 25(22).

PMID: 39596223 PMC: 11594830. DOI: 10.3390/ijms252212157.


Animal models of mucosal infections.

Assoni L, Couto A, Vieira B, Milani B, Lima A, Converso T Front Microbiol. 2024; 15:1367422.

PMID: 38559342 PMC: 10978692. DOI: 10.3389/fmicb.2024.1367422.


Spinal Cord Injury Impairs Lung Immunity in Mice.

Mifflin K, Brennan F, Guan Z, Kigerl K, Filous A, Mo X J Immunol. 2022; 209(1):157-170.

PMID: 35697382 PMC: 9246940. DOI: 10.4049/jimmunol.2200192.


Acquisition of ionic copper by the bacterial outer membrane protein OprC through a novel binding site.

Bhamidimarri S, Young T, Shanmugam M, Soderholm S, Basle A, Bumann D PLoS Biol. 2021; 19(11):e3001446.

PMID: 34762655 PMC: 8610252. DOI: 10.1371/journal.pbio.3001446.


References
1.
De Simone M, Spagnuolo L, Lore N, Rossi G, Cigana C, De Fino I . Host genetic background influences the response to the opportunistic Pseudomonas aeruginosa infection altering cell-mediated immunity and bacterial replication. PLoS One. 2014; 9(9):e106873. PMC: 4182038. DOI: 10.1371/journal.pone.0106873. View

2.
Ambrose P, Bhavnani S, Owens Jr R . Clinical pharmacodynamics of quinolones. Infect Dis Clin North Am. 2004; 17(3):529-43. DOI: 10.1016/s0891-5520(03)00061-8. View

3.
Miles T, Hennessy A, Bax B, Brooks G, Brown B, Brown P . Novel hydroxyl tricyclics (e.g., GSK966587) as potent inhibitors of bacterial type IIA topoisomerases. Bioorg Med Chem Lett. 2013; 23(19):5437-41. DOI: 10.1016/j.bmcl.2013.07.013. View

4.
Eagle H, FLEISCHMAN R, Musselman A . The bactericidal action of penicillin in vivo: the participation of the host, and the slow recovery of the surviving organisms. Ann Intern Med. 1950; 33(3):544-71. DOI: 10.7326/0003-4819-33-3-544. View

5.
Drusano G, Fregeau C, Liu W, Brown D, Louie A . Impact of burden on granulocyte clearance of bacteria in a mouse thigh infection model. Antimicrob Agents Chemother. 2010; 54(10):4368-72. PMC: 2944594. DOI: 10.1128/AAC.00133-10. View